Table 2 GTMP and Tropical Data
From: Trachoma
Characteristic | GTMP | Tropical Dataa |
|---|---|---|
Dates of operation | December 2012–January 2016 | February 2016 onwards |
Survey types supported | Baseline | Baseline, impact, surveillance and TT-only |
Funding | UK Department for International Development and US Agency for International Development | Core Tropical Data funding from the International Trachoma Initiative, Sightsavers and RTI International; countries are responsible for funding the surveys themselves with support from partners |
Primary unit of reporting to funding agencies | Districts, as defined by the country, resulting in different population sizes and geographical areas | EUs, each comprising a population of ~100,000–250,000 people288, making process data more comparable |
QA and QC | Developed and implemented globally standardized methodologies for epidemiologically robust population-based trachoma prevalence surveys with QA and QC at every step of the survey process125,126 | Developed GTMP QA and QC methods further, including the incorporation of 3D goggles for TT training289,290; incorporation of follicle size guides to aid TF diagnosis116; and longer data recorder training, data recorder reliability test and greater emphasis on supervision128 |
Number of countries supported | 29 | 45 |
Number of people examined | >2.6 million | >6.8 million |
Number of evaluation units surveyed | 905 | 2,200 |
Impact | Baseline mapping of all accessible suspected trachoma-endemic countries; active trachoma was confirmed to be a public health problem in 341 of 905 EUs (38%) surveyed; TT was confirmed to be a public health problem in 473 of 905 EUs (52%) | 445 baseline, 1,036 impact, 491 surveillance and 141 TT-only surveys supported; helped confirm that MDA should be started or continued in 586 EUs; MDA was not needed in 332 EUs; MDA could be stopped in 638 EUs; and trachoma no longer a public health problem in 416 EUs |
